The role of the data coordinating center in the IRB review and approval process: the DIG trial experience

被引:7
作者
Collins, JF
Garg, R
Teo, KK
Williford, WO
Howell, CL
机构
[1] Cooperat Studies Program Coordinat Ctr, Dept Vet Affairs, Perry Point, MD USA
[2] Univ Maryland, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA
[3] NHLBI, Rockville, MD USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada
来源
CONTROLLED CLINICAL TRIALS | 2003年 / 24卷 / 06期
关键词
data coordinating center responsibilities; institutional review boards; OHRP; patient rights; patient safety;
D O I
10.1016/S0197-2456(03)00100-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Before any clinical trial can begin to recruit patients, participating clinical centers must obtain approval from their institutional review board (IRB). When studies are federally funded, such as by the U.S. Department of Health and Human Services (DHHS), centers must also have or obtain a federal compliance agreement from the Office of Human Research Protections (formerly the Office for Protection from Research Risks [OPRR]). The Digitalis Investigation Group trial was a large, international, double-blind, DHHS-funded randomized trial on the effect of digoxin on mortality in heart failure. Due to the anticipated number of centers (>200), the study's data coordinating center (DCC) was requested to assume additional responsibilities that included: (1) acting as a liaison between the OPRR and all study centers; (2) reviewing and correcting all assurance statements before submission to the OPRR; (3) reviewing and approving all centers' informed consent forms; and (4) helping the many research-inexperienced centers to establish IRBs or to locate an IRB in their region that would accept IRB responsibility for them. Although a heavy burden was placed on the DCC, the IRB and OPRR approval process was probably shortened by many weeks at those centers not already possessing a federal compliance agreement. This enabled the study to be completed on schedule and within budget. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:306S / 315S
页数:10
相关论文
共 10 条
  • [1] Abernathy GT, 1996, CONTROL CLIN TRIALS, V17, P77
  • [2] [Anonymous], 1979, BELM REP ETH PRINC G
  • [3] [Anonymous], PROT HUM RES SUBJ I
  • [4] MASTROIANNI AC, 1994, WOMEN HLTH RES ETHIC, V1, P128
  • [5] The effect of spironolactone on morbidity and mortality in patients with severe heart failure
    Pitt, B
    Zannad, F
    Remme, WJ
    Cody, R
    Castaigne, A
    Perez, A
    Palensky, J
    Wittes, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) : 709 - 717
  • [6] SIEBER JE, 1992, PLANNING ETHICALLY R, V31, P3
  • [7] *US DEP HHS, 1991, COD FED REG, V45
  • [8] *US DEP HHS, 2001, FED ASS PROT HUM SUB
  • [9] *US DEP HHS, 2001, I REV BOARD IND ETH
  • [10] VEATCH RM, 1989, MED ETHICS INTRO, P14